Salarius Pharmaceuticals Stock Cash And Equivalents

SLRX Stock

USD 1.43 0.02 1.38%

Salarius Pharmaceuticals fundamentals help investors to digest information that contributes to Salarius Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Salarius Stock. The fundamental analysis module provides a way to measure Salarius Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Salarius Pharmaceuticals stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Salarius Pharmaceuticals Company Cash And Equivalents Analysis

Salarius Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Salarius Pharmaceuticals Cash And Equivalents

22.65 M

Most of Salarius Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Salarius Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Salarius Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Salarius Pharmaceuticals is extremely important. It helps to project a fair market value of Salarius Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Salarius Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Salarius Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Salarius Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Intangible Assets	Net Invested Capital	Net Working Capital	Capital Stock	Good Will	Short Long Term Debt	Short Term Debt
Total Assets		0.74	-0.87	0.24	0.39	0.11	0.99	0.26	0.46	0.52	0.43	0.5	-0.64	-0.44	-0.56	0.7	0.73	0.42	0.52	0.41	0.41
Total Stockholder Equity	0.74		-0.41	-0.25	0.58	-0.58	0.71	0.56	-0.2	0.06	0.16	-0.17	-0.09	-0.02	-0.06	0.25	0.2	0.27	0.18	0.03	0.03
Net Debt	-0.87	-0.41		-0.43	-0.07	-0.45	-0.88	-0.05	-0.8	-0.6	-0.4	-0.8	0.71	0.59	0.64	-0.72	-0.79	-0.42	-0.48	-0.39	-0.39
Retained Earnings	0.24	-0.25	-0.43		-0.41	0.65	0.17	-0.23	0.72	-0.05	0.31	0.63	-0.33	0.15	-0.08	0.47	0.35	0.21	0.35	0.24	0.24
Accounts Payable	0.39	0.58	-0.07	-0.41		-0.38	0.39	0.3	-0.4	0.23	0.34	-0.27	-0.25	-0.1	-0.21	0.25	0.26	0.06	0.18	0.19	0.19
Total Liab	0.11	-0.58	-0.45	0.65	-0.38		0.15	-0.52	0.84	0.54	0.29	0.86	-0.65	-0.5	-0.59	0.48	0.59	0.11	0.37	0.46	0.46
Total Current Assets	0.99	0.71	-0.88	0.17	0.39	0.15		0.16	0.48	0.6	0.38	0.54	-0.69	-0.54	-0.62	0.65	0.73	0.34	0.46	0.42	0.42
Common Stock	0.26	0.56	-0.05	-0.23	0.3	-0.52	0.16		-0.36	-0.14	0.22	-0.43	0.25	0.19	0.17	0.38	0.16	0.79	0.32	-0.18	-0.18
Net Tangible Assets	0.46	-0.2	-0.8	0.72	-0.4	0.84	0.48	-0.36		0.5	0.26	0.97	-0.67	-0.51	-0.56	0.55	0.65	0.22	0.36	0.38	0.38
Capital Surpluse	0.52	0.06	-0.6	-0.05	0.23	0.54	0.6	-0.14	0.5		0.45	0.66	-0.72	-0.87	-0.99	0.52	0.73	0.24	0.59	0.72	0.72
Deferred Long Term Liab	0.43	0.16	-0.4	0.31	0.34	0.29	0.38	0.22	0.26	0.45		0.34	-0.21	-0.13	-0.54	0.6	0.52	0.46	0.74	0.53	0.53
Property Plant Equipment	0.5	-0.17	-0.8	0.63	-0.27	0.86	0.54	-0.43	0.97	0.66	0.34		-0.75	-0.6	-0.72	0.55	0.69	0.14	0.46	0.56	0.56
Current Deferred Revenue	-0.64	-0.09	0.71	-0.33	-0.25	-0.65	-0.69	0.25	-0.67	-0.72	-0.21	-0.75		0.72	0.73	-0.69	-0.86	-0.19	-0.36	-0.48	-0.48
Net Receivables	-0.44	-0.02	0.59	0.15	-0.1	-0.5	-0.54	0.19	-0.51	-0.87	-0.13	-0.6	0.72		0.82	-0.42	-0.69	-0.16	-0.23	-0.34	-0.34
Intangible Assets	-0.56	-0.06	0.64	-0.08	-0.21	-0.59	-0.62	0.17	-0.56	-0.99	-0.54	-0.72	0.73	0.82		-0.57	-0.76	-0.24	-0.67	-0.78	-0.78
Net Invested Capital	0.7	0.25	-0.72	0.47	0.25	0.48	0.65	0.38	0.55	0.52	0.6	0.55	-0.69	-0.42	-0.57		0.93	0.79	0.73	0.41	0.41
Net Working Capital	0.73	0.2	-0.79	0.35	0.26	0.59	0.73	0.16	0.65	0.73	0.52	0.69	-0.86	-0.69	-0.76	0.93		0.62	0.62	0.45	0.45
Capital Stock	0.42	0.27	-0.42	0.21	0.06	0.11	0.34	0.79	0.22	0.24	0.46	0.14	-0.19	-0.16	-0.24	0.79	0.62		0.64	0.13	0.13
Good Will	0.52	0.18	-0.48	0.35	0.18	0.37	0.46	0.32	0.36	0.59	0.74	0.46	-0.36	-0.23	-0.67	0.73	0.62	0.64		0.81	0.81
Short Long Term Debt	0.41	0.03	-0.39	0.24	0.19	0.46	0.42	-0.18	0.38	0.72	0.53	0.56	-0.48	-0.34	-0.78	0.41	0.45	0.13	0.81		1.0
Short Term Debt	0.41	0.03	-0.39	0.24	0.19	0.46	0.42	-0.18	0.38	0.72	0.53	0.56	-0.48	-0.34	-0.78	0.41	0.45	0.13	0.81	1.0

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Salarius Pharmaceuticals

Salarius Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

10.09 Million

At this time, Salarius Pharmaceuticals' Cash And Cash Equivalents Changes is fairly stable compared to the past year.

In accordance with the recently published financial statements, Salarius Pharmaceuticals has 22.65 M in Cash And Equivalents. This is 97.24% lower than that of the Biotechnology sector and 94.93% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.16% higher than that of the company.

Salarius Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Salarius Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Salarius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics of similar companies.

Salarius Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.

Salarius Fundamentals

	Return On Equity	-1.2
	Return On Asset	-0.54
	Current Valuation	(865.5 K)
	Shares Outstanding	1.44 M
	Shares Owned By Insiders	2.52 %
	Shares Owned By Institutions	0.36 %
	Number Of Shares Shorted	54.98 K
	Price To Book	0.71 X
	Price To Sales	18.12 X
	Gross Profit	(15.84 M)
	EBITDA	(2.84 K)
	Net Income	(12.54 M)
	Cash And Equivalents	22.65 M
	Cash Per Share	10.09 X
	Total Debt	289.64 K
	Debt To Equity	0 %
	Current Ratio	8.31 X
	Book Value Per Share	10.74 X
	Cash Flow From Operations	(12.85 M)
	Short Ratio	0.08 X
	Earnings Per Share	(5.14) X
	Target Price	26.0
	Beta	0.93
	Market Capitalization	2.09 M
	Total Asset	6.59 M
	Retained Earnings	(76.35 M)
	Working Capital	5.22 M
	Current Liabilities	1.97 M
	Net Asset	6.59 M

About Salarius Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Salarius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Salarius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Salarius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC